IEDAT SIGNED
Intra Erythrocyte Dexamethasone in the treatment of Ataxia Telangiectasia
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0IEDAT project word cloud
Explore the words cloud of the IEDAT project. It provides you a very rough idea of what is the project "IEDAT" about.
Project "IEDAT" data sheet
The following table provides information about the project.
| Coordinator |
EryDel S.p.A.
Organization address contact info |
| Coordinator Country | Italy [IT] |
| Project website | http://iedat-project.eu/ |
| Total cost | 5˙871˙825 € |
| EC max contribution | 5˙871˙825 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-PHC-2015-two-stage |
| Funding Scheme | RIA |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-01-01 to 2021-02-28 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | EryDel S.p.A. | IT (Bresso) | coordinator | 4˙331˙575.00 |
| 2 | Universita' degli Studi di Urbino Carlo Bo | IT (URBINO) | participant | 400˙000.00 |
| 3 | MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER | IL (RAMAT GAN) | participant | 270˙000.00 |
| 4 | JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN | DE (FRANKFURT AM MAIN) | participant | 256˙250.00 |
| 5 | THE ATAXIA-TELANGIECTASIA SOCIETY | UK (HARPENDEN) | participant | 254˙000.00 |
| 6 | JOHNS HOPKINS UNIVERSITY | US (BALTIMORE) | participant | 217˙500.00 |
| 7 | AK GROUP | FR (ANGERS) | participant | 142˙500.00 |
| 8 | ABSISKEY | FR (ANGERS) | participant | 0.00 |
| 9 | ABSISKEY CP | FR (GRENOBLE) | participant | 0.00 |
Map
Project objective
The main objective of the project is to provide a treatment of the neurological symptoms of patients with Ataxia Telangiectasia (AT), a rare progressively disabling and life-shortening genetic disease for which no therapy is currently available. To achieve this, a pivotal Phase III study will be conducted, to allow regulatory filing to obtain market authorization in EU and USA by 2019. EryDex is an innovative product, developed by EryDel, used to administer dexamethasone sodium phosphate by ex-vivo encapsulation in autologous erythrocytes, which are infused into the patient. EryDex provides long-term delivery of low doses of dexamethasone without the typical steroid side effects and has reached a successful Phase II trial conducted in AT patients. The phase III trial will be an international, multi-center, 1 year, randomized, prospective, double-blind, placebo-controlled, designed to assess the effect of 2 dose ranges of EryDex, administered monthly by IV infusion, on neurological symptoms of AT patients. The protocol of the trial and the regulatory path to registration has already been agreed upon with EMA and FDA. An international patient registry will also be set with the aim of establishing and maintaining a comprehensive clinical database of patients with AT and closely related conditions, enabling the monitoring of AT epidemiology, the development of an evidence-based natural history of the condition, identification of biomarkers as well as development of clinical guidelines. The AT NEST, the first scale to assess symptoms specific to AT patients, coordinated by the AT centre at the John’s Hopkins University, will be tested in the study and if validated will represent the 1st scale assessing chief areas of impairment specific to AT. In parallel to the clinical trial, investigations into the molecular mechanisms of action of EryDex will be performed with the objective to provide the validation of a new biomarker predictive of treatment efficacy.
Deliverables
| Dissemination materials | Websites, patent fillings, videos etc. | 2020-04-09 09:40:08 |
| Registration number of clinical study in approved registry | Documents, reports | 2020-04-09 09:40:08 |
| Registry database | Other | 2020-04-09 09:40:08 |
| Project website (IEDAT) | Websites, patent fillings, videos etc. | 2020-04-09 09:40:08 |
| Report on AT NEST definition, guidelines and SOPs | Documents, reports | 2020-04-09 09:40:08 |
| First evaluation workshop | Documents, reports | 2020-04-09 09:40:08 |
Take a look to the deliverables list in detail: detailed list of IEDAT deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Giovanni Mambrini, Marco Mandolini, Luigia Rossi, Francesca Pierigè, Giovanni Capogrossi, Patricia Salvati, Sonja Serafini, Luca Benatti, Mauro Magnani Ex vivo encapsulation of dexamethasone sodium phosphate into human autologous erythrocytes using fully automated biomedical equipment published pages: 175-184, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2016.12.011 |
International Journal of Pharmaceutics 517/1-2 | 2020-04-09 |
| 2018 |
Michele Menotta, Sara Biagiotti, Sara Orazi, Luigia Rossi, Luciana Chessa, Vincenzo Leuzzi, Daniela D’Agnano, Alessandro Plebani, Annarosa Soresina, Mauro Magnani In vivo effects of dexamethasone on blood gene expression in ataxia telangiectasia published pages: 153-166, ISSN: 0300-8177, DOI: 10.1007/s11010-017-3122-x |
Molecular and Cellular Biochemistry 438/1-2 | 2020-04-09 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IEDAT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IEDAT" are provided by the European Opendata Portal: CORDIS opendata.